Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

42.47 -0.51 (-1.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CG Oncology, Inc. - Common stock

< Previous 1 2 Next >
Why Cg Oncology Stock Rocketed 7% Higher Today
One pundit believes this is a clinical-stage company well worth watching. 
Via The Motley Fool
CG Oncology Stock Signals Bullish Momentum Ahead
CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track... 
Via Benzinga
Cg Oncology (CGON) Q2 Loss Widens 93%
Via The Motley Fool
Which stocks are moving before the opening bell on Tuesday?
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
3 Analysts Assess CG Oncology: What You Need To Know
 
Via Benzinga
Why CG Oncology (CGON) Stock Is Down 9%
CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock. 
Via Benzinga
Demystifying CG Oncology: Insights From 7 Analyst Reviews
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock
 
Via Benzinga
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
A Closer Look at 9 Analyst Recommendations For CG Oncology
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook
 
Via Benzinga
Which stocks are gapping on Monday?
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025. 
Via Benzinga
These stocks are moving in today's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
The companies are working on treatments for a form of bladder cancer. 
Via Investor's Business Daily
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Friday's after hours session: top gainers and losers
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts
 
Via Benzinga
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
Nasdaq Jumps 300 Points To Record Highs
Stocks are higher this afternoon, after this morning's highly-anticipated CPI report met expectations. 
Via Talk Markets
Topics Stocks / Equities
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate
CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients, with median DOR exceeding 27 months and no severe side effects. 
Via Benzinga
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise. 
Via MarketBeat
Topics Initial Public Offering
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.